Jun 4, 2026, 15:53
Rituximab and Eculizumab in Refractory Antiphospholipid Syndrome – APS Foundation of America
APS Foundation of America shared a post on LinkedIn:
“Rituximab and Eculizumab Show Benefit in Refractory Antiphospholipid Syndrome
Key Point: Across biologic therapies for antiphospholipid syndrome APS), rituximab and eculizumab had the most robust data, while belimumab and daratumumab were promising but supported by very limited early evidence.
‘Ultimately, personalized strategies integrating clinical phenotype, serology, and pathogenic mechanisms may offer the best approach for optimizing care in patients with refractory or complex APS.'”
Read More.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Jul 25, 2026, 10:56PMOS Can Affect Much More Than Periods or Fertility – PCOS Awareness Association
-
Jul 25, 2026, 10:42Asma Khalil: Recreational Drug Use During Pregnancy, What Every Expectant Mother Should Know!
-
Jul 25, 2026, 10:40Khalil Faaed: Are Complex Y Chromosome Rearrangements the Missing Link in Unexplained Male Infertility?
-
Jul 25, 2026, 10:38Sean Lauber: Does Transferring a Cleavage or Blastocyst Stage Embryo Affect the Chance of Having a Boy?
-
Jul 25, 2026, 10:33Rokaya Hachicho: The Hidden Cost of Excessive Laser Use During Trophectoderm Biopsy!
-
Jul 25, 2026, 10:31Join the ISUOG Webinar on Late-Evolving Fetal Anomalies – ISUOG
-
Jul 25, 2026, 10:29Waiting Before Clamping the Umbilical Cord Improves Neonatal Outcomes! – RCOG
-
Jul 25, 2026, 10:27Christopher Robinson: The Impact of Body Mass Index on Misoprostol Dosing for Labor Induction!
-
Jul 25, 2026, 10:26Heavy Menstrual Bleeding and Dysmenorrhea in Adolescents – IJGO